Yufeng Du

Yufeng Du

Auto-generated profile, based on publicly available information

Yufeng Du

Department of Hematology, Dalian Key Laboratory of Hematology, Liaoning Medical Center for Hematopoietic Stem Cell Transplantation The Second Hospital of Dalian Medical University Dalian China

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 April 2023 in Hematology
Verified
Journal Article
Open access
YDYufeng Du
Yufeng Du
CLChunhong Li
Chunhong Li
JYJinsong Yan
Jinsong Yan
The meta-analysis sought to evaluate the efficacy and safety of a combination of venetoclax (Ven) and azacitidine (AZA) in the treatment of acute myeloid leukemia (AML) and myelodysplastic syndrome...

29 December 2025 in Cancer Reports
Verified
Journal Article
Open access
YDYufeng Du
Yufeng Du
MHMohammad Arian Hassani
Mohammad Arian Hassani
CLChunhong Li
Chunhong Li
ZZZhijia Zhao
Zhijia Zhao
YLYikun Liu
Yikun Liu
JYJinsong Yan
Jinsong Yan
Background: Refractory/relapsed acute myeloid leukemia (R/R‐AML) typically exhibits resistance to conventional chemotherapy, resulting in a poor overall therapeutic outcome. Salvage allogeneic hematopoietic stem cell transplantation (allo‐HSCT) is the primary treatment option in such patients. However, posttransplant relapse is still a challenge, with no established effective regimens. Case: In this case report, we present the case of a 40‐year‐old male diagnosed with R/R‐AML who underwent salvage allo‐HSCT. Unfortunately, after 4 months of follow‐up, a relapse occurred. We modified the immunosuppressive therapy and administered donor lymphocyte infusion (DLI) and decitabine but failed to obtain complete remission (CR). Subsequently, a combination of venetoclax (Ven) and azacitidine (Aza), followed by the DLI regimen, was initiated. The patient achieved CR with no measurable residual disease. Conclusion: Our data suggest that the administration of Ven in combination with Aza followed by the DLI regimen used for early post‐HSCT relapsed AML could serve as a valuable reference for treating similar patients.